scholarly journals Controlled Release Imatinib Mesylate Tablet Formulation: Using Hydrophilic Matrix System

2015 ◽  
Vol 21 (3) ◽  
pp. 157-166 ◽  
Author(s):  
Ehsan Mohajeri ◽  
Mehdi Ansari ◽  
Abbas Pardakhty
Keyword(s):  
Controlled Release ◽  
Imatinib Mesylate ◽  
Tablet Formulation ◽  
Matrix System ◽  
Hydrophilic Matrix ◽  
Hydrophilic Matrix System

Development of a modified-release hydrophilic matrix system of a plant extract based on co-spray-dried powders

2013 ◽  
Vol 241 ◽  
pp. 252-262 ◽  
Author(s):  
Loreana Gallo ◽  
Juliana Piña ◽  
Verónica Bucalá ◽  
Daniel Allemandi ◽  
María Verónica Ramírez-Rigo
Keyword(s):  
Plant Extract ◽  
Matrix System ◽  
Modified Release ◽  
Hydrophilic Matrix ◽  
Hydrophilic Matrix System ◽  
Spray Dried

Design and Evaluation of Hydrophilic Matrix System for pH-Independent Sustained Release of Weakly Acidic Poorly Soluble Drug

2018 ◽  
Vol 19 (5) ◽  
pp. 2144-2154 ◽  
Author(s):  
Jinheng Huang ◽  
Huaqing Lin ◽  
Bingxin Peng ◽  
Qianfeng Huang ◽  
Fangzhou Shuai ◽  
...  
Keyword(s):  
Sustained Release ◽  
Matrix System ◽  
Hydrophilic Matrix ◽  
Hydrophilic Matrix System ◽  
Poorly Soluble ◽  
Poorly Soluble Drug

scholarly journals Novel hydrophilic matrix system with non-uniform drug distribution for zero-order release kinetics

2018 ◽  
Vol 287 ◽  
pp. 247-256 ◽  
Author(s):  
Matteo Cerea ◽  
Alessandra Maroni ◽  
Luca Palugan ◽  
Marco Bellini ◽  
Anastasia Foppoli ◽  
...  
Keyword(s):  
Release Kinetics ◽  
Drug Distribution ◽  
Zero Order ◽  
Matrix System ◽  
Hydrophilic Matrix ◽  
Order Release ◽  
Zero Order Release ◽  
Hydrophilic Matrix System

N-Acetylserotonin vs Melatonin: In-Vitro Controlled Release from Hydrophilic Matrix Tablets

2019 ◽  
Vol 16 (3) ◽  
pp. 347-352 ◽  
Author(s):  
M. Vlachou ◽  
G. Stavrou ◽  
A. Siamidi ◽  
S. Flitouri ◽  
V. Ioannidou ◽  
...  
Keyword(s):  
Controlled Release ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Sleep Onset ◽  
Matrix Tablets ◽  
Melatonin Receptors ◽  
Solid Matrix ◽  
Poor Sleep ◽  
Prolonged Release ◽  
Hydrophilic Matrix

Background: N-Acetylserotonin (NAS, N-acetyl-5-hydroxytryptamine) is the immediate precursor of the neurohormone melatonin (MT, N-acetyl-5-methoxytryptamine), which regulates sleep and wake cycles. NAS is produced by the N-acetylation of serotonin and is converted to melatonin via the action of Acetylserotonin O-methyltransferase (ASMT). Like melatonin, NAS acts as an agonist on the melatonin receptors MT1, MT2, and MT3. However, as NAS is abundant in specific brain areas, separate from serotonin and melatonin, it may also have discrete central effects. Indicatively, it has been reported that NAS may play a role in the antidepressant effects of Selective Serotonin Reuptake Inhibitors (SSRIs) and Monoamine Oxidase Inhibitors (MAOIs). </P><P> Objective: To decipher the controlled release characteristics of the active substances (NAS and MT) in a quick initial pace, aiming at a satisfactory sleep-onset related anti-depressive profile and prolonged release, thereafter, targeting at coping with poor sleep quality problems. </P><P> Methods: A series of hydrophilic matrix tablets involving as excipients, hydroxypropylmethylcellulose (HPMC) K15M, low viscosity sodium alginate, lactose monohydrate, and polyvinylpyrrolidone (PVP) M.W.: 10.000 and 55.000) was developed and tested at two dissolution media (pH 1.2 and 7.4). </P><P> Results: The results showed that commonly used excipients with different physicochemical properties govern the controlled release of NAS and MT from solid matrix systems. </P><P> Conclusions: We have demonstrated how broadly used excipients affect the in vitro controlled release of NAS and MT from solid pharmaceutical formulations. Currently, we extend our studies on the controlled release of these drugs using various other biopolymers/formulants of different physicochemical characteristics, which will help to highlight the discrete release profiles of NAS and MT.

scholarly journals Predicting absorption and pharmacokinetic profile of carbamazepine from controlled-release tablet formulation in humans using rabbit model

2011 ◽  
Vol 65 (1-2) ◽  
pp. 71-81
Author(s):  
Irena Homsek ◽  
Dragica Popadic ◽  
Slobodanka Simic ◽  
Slavica Ristic ◽  
Katarina Vucicevic ◽  
...  
Keyword(s):  
Controlled Release ◽  
Rabbit Model ◽  
Tablet Formulation ◽  
Human Model ◽  
In Vitro Dissolution ◽  
Pharmacokinetic Parameters ◽  
Pharmacokinetic Data ◽  
Drug Concentrations

Controlled-release (CR) pharmaceutical formulations offer several advantages over the conventional, immediate release dosage forms of the same drug, including reduced dosing frequency, decreased incidence and/or intensity of adverse effects, greater selectivity of pharmacological activity, reduced drug plasma fluctuation, and better compliance. After a drug product has been registered, and is already on market, minor changes in formulation might be needed. At the same time, the product has to remain effective and safe for patients that could be confirmed via plasma drug concentrations and pharmacokinetic characteristics. It is challenging to predict human absorption and pharmacokinetic characteristics of a drug based on the in vitro dissolution test and the animal pharmacokinetic data. Therefore, the objective of this study was to establish correlation of the pharmacokinetic parameters of carbamazepine (CBZ) CR tablet formulation between the rabbit and the human model, and to establish in vitro in vivo correlation (IVIVC) based on the predicted fractions of absorbed CBZ. Although differences in mean plasma concentration profiles were notified, the data concerning the predicted fraction of drug absorbed were almost superimposable. Accordingly, it can be concluded that rabbits may be representative as an in vivo model for predicting the pharmacokinetics of the CR formulation of CBZ in humans.

Sign in / Sign up

Export Citation Format

Share Document